RedHill Reports Opaganib Reduces COVID-19 Deaths
Company Announcements

RedHill Reports Opaganib Reduces COVID-19 Deaths

RedHill Biopharma (RDHL) has released an update.

RedHill Biopharma Ltd. has reported a significant reduction in mortality rates among moderate to severe COVID-19 pneumonia patients treated with their drug opaganib. The published post-hoc analysis from a phase 2/3 study shows a 62% decrease in death rates and a 21% improvement in recovery times. These results indicate that opaganib, an orally administered treatment with a favorable safety profile, could be a promising new therapy for hospitalized COVID-19 patients.

For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskRedHill Biopharma to Present Opaganib at U.S. Defense Conference
TipRanks Auto-Generated NewsdeskRedHill Biopharma and Duke Collaborate on Opaganib Development
TheFlyRedHill Biopharma signs research pact with Duke University School of Medicine
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App